Management of Bone Tumors

Diagnostic Approach

Initial evaluation should include appropriate imaging: plain radiographs followed by CT scan as first-line investigation, with MRI indicated for suspected neurological complications, according to the National Comprehensive Cancer Network 3, 4
In patients under 40 years with an aggressive, symptomatic bone lesion, referral to an orthopedic oncologist should be considered before further workup due to significant risk of primary bone malignancy, as recommended by the National Comprehensive Cancer Network 5
In patients 40 years or older, workup for potential bone metastasis is recommended, including bone scan, chest x-ray, and CT of chest/abdomen/pelvis with contrast, as suggested by the National Comprehensive Cancer Network 5

Treatment requires a multidisciplinary approach involving pathologists, radiologists, surgeons, radiation and medical oncologists at specialized centers, according to the British Journal of Cancer 1
For Ewing sarcoma, compressed VDC/IE (vincristine, doxorubicin, cyclophosphamide, ifosfamide, etoposide) is the preferred first-line treatment for medically fit patients, as recommended by the British Journal of Cancer 6
Specific indications for postoperative radiotherapy in Ewing sarcoma include positive surgical margins, poor response to chemotherapy, and large tumors in high-risk areas, according to the British Journal of Cancer 6
For chordoma, high-dose radiation therapy including proton or carbon ion beam RT is recommended, especially for skull base tumors, as suggested by the Annals of Oncology 7

Multimodality treatment with neoadjuvant chemotherapy, surgery, and adjuvant chemotherapy has improved 5-year survival to 60-70% in localized osteosarcoma, as reported by the National Comprehensive Cancer Network 5
Multimodality treatment improves 5-year survival to almost 80% in localized Ewing sarcoma and 20-40% in metastatic disease, according to the British Journal of Cancer 6
Local treatment decisions require discussion between bone sarcoma MDT, patient, and family, as recommended by the British Journal of Cancer 6
Primarily surgical management is recommended for chondrosarcoma, as most subtypes are chemoresistant, according to the Annals of Oncology 7
Denosumab is standard treatment for unresectable or metastatic giant cell tumor of bone, as suggested by the Annals of Oncology 7
En bloc R0 resection is standard treatment when feasible for chordoma, according to the Annals of Oncology 7

Management strategy based on fracture risk and neurological risk evaluation, as recommended by the Cancer and Metastasis Reviews 3, 4
Modern management integrates focal treatments (radiotherapy, surgery, interventional radiology), orthoses, and antiresorptive and systemic oncological treatment, according to the Cancer and Metastasis Reviews 3
Treatment choice depends on pain, neurological risk, bone instability, patient characteristics, and treatment objectives, as suggested by the Cancer and Metastasis Reviews 8
Multidisciplinary approach must include rehabilitation, systemic treatment, antiresorptive treatment, and supportive care, according to the Cancer and Metastasis Reviews 4

Follow-up of high-grade tumors should include physical examination of tumor site, assessment of function, and possible complications of reconstruction, as recommended by the Annals of Oncology 7
Recommended intervals: every 3 months for first 2 years; every 6 months for years 3-5; every 6-12 months for years 5-10; every 0.5-2 years thereafter, according to the Annals of Oncology 7
Imaging should include local imaging and chest X-ray/CT, as suggested by the Annals of Oncology 7
Long-term monitoring for toxic effects of chemotherapy, surgery, and radiation therapy should continue for >10 years after treatment, according to the Annals of Oncology 7

Delayed referral to specialized centers can negatively impact outcomes, as reported by the British Journal of Cancer 1
Secondary cancers may arise in survivors of bone sarcomas, either related to or independent of irradiation, according to the Annals of Oncology 7
Long-term cardiac evaluation is important as deterioration of cardiac function can occur decades after anthracycline treatment, as suggested by the Annals of Oncology 7